Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Woodall

Neurological Surgery Athens, GA Medical Doctor

NPI 1144458662 CMS profile 233170

2142 W Broad St, Bldg 100, Ste 200, Ste 103, Athens, GA 30606

Open in the dashboard

General payments

$8,565

85 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Woodall of Athens, GA is reported in the CMS Open Payments database as having received $8,565 across 85 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $604 3
2024 General $2,003 16
2023 General $184 3
2022 General $2,646 16
2021 General $1,251 15
2020 General $591 19
2019 General $1,285 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Woodall
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Michael Woodall were reported at $604. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Michael Woodall Neurological Surgery median Middle half National median
2019 $1,285 $582 $138–$3,006 $163
2020 $591 $294 $76–$2,174 $114
2021 $1,251 $387 $105–$2,432 $132
2022 $2,646 $542 $139–$2,989 $149
2023 $184 $534 $145–$2,697 $160
2024 $2,003 $574 $155–$3,046 $164
2025 $604 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Globus Medical, Inc. $2,857 19 payments
  2. Abbott Laboratories $2,606 15 payments
  3. Medtronic USA, Inc. $1,326 22 payments
  4. Medtronic, Inc. $601 15 payments
  5. BIOTRONIK NRO, Inc. $429 1 payment
  6. Zimmer Biomet Holdings, Inc. $189 3 payments
  7. Stryker Corporation $141 2 payments
  8. Intrinsic Therapeutics $136 1 payment
  9. Penumbra, Inc. $136 1 payment
  10. Boston Scientific Corporation $91 2 payments
  11. Other $55 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $5,439 21 payments
  2. Food and Beverage $2,937 61 payments
  3. Education $189 3 payments
Products named General payments · program years 2019–2025
  1. PROCLAIM Neuromodulation $2,175 10 payments
  2. ExcelsiusGPS Robotic Navigation System $919 6 payments
  3. DIVERGENCE-L $890 5 payments
  4. EXCELSIUS GPS $825 6 payments
  5. Prospera $429 1 payment
  6. PROCLAIM Neuromodulation $243 2 payments
  7. MAZOR X SYSTEM $222 2 payments
  8. PIVOX Oblique Lateral Spinal System $194 3 payments
  9. MONUMENT $190 1 payment
  10. Biomet SpinalPak $189 3 payments
  11. Other $1,954 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

249

Median for Neurosurgery: 83

Drug cost

$1,761

Median for Neurosurgery: $872

Branded share of claims

32.1%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cyclobenzaprine Hcl Generic 45 $331
Oxycodone Hcl Generic 52 $317
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 29 $289
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 39 $283
Gabapentin Generic 22 $160
Clopidogrel Clopidogrel Bisulfate Brand 12 $143
Methocarbamol Generic 27 $109
Tizanidine Hcl Generic 12 $74
Methylprednisolone Generic 11 $56

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 101 billing codes

Paid by Medicare

$190,387

Medicare's payments for the services billed

Medicare patients

225

Average age 73

Services billed

699

128 women, 97 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 72%
Ischemic heart disease 36%
Diabetes 33%
Depression 30%
Chronic kidney disease 25%
Atrial fibrillation 24%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record